Abstract:The COVID-19 pandemic is spreading globally with high disparity in the susceptibility of the disease severity. Identification of the key underlying factors for this disparity is highly warranted. Here we describe constructing a proteomic risk score based on 20 blood proteomic biomarkers which predict the progression to severe COVID-19. We demonstrate that in our own cohort of 990 individuals without infection, this proteomic risk score is positively associated with proinflammatory cytokines mainly among older, but not younger, individuals. We further discovered that a core set of gut microbiota could accurately predict the above proteomic biomarkers among 301 individuals using a machine learning model, and that these gut microbiota features are highly correlated with proinflammatory cytokines in another set of 366 individuals. Fecal metabolomic analysis suggested potential amino acid-related pathways linking gut microbiota to inflammation. This study suggests that gut microbiota may underlie the predisposition of normal individuals to severe COVID-19. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was funded by the National Natural Science Foundation of China (81903316, 81773416, 81972492, 21904107, 81672086), Zhejiang Ten-thousand Talents Program (101396522001), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), the 5010 Program for Clinical Researches (2007032) of the Sun Yat-sen University, Hangzhou Agriculture and Society Advancement Program (20190101A04), and Tencent foundation (2020). The funder had no role in study design, data collection and analysis, decision to publish, or writing of the manuscript. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The raw data of 16 S rRNA gene sequences are available at CNSA (<https://db.cngb.org/cnsa/>) of CNGBdb at accession number CNP0000829. <https://db.cngb.org/cnsa/>

Microbiome Profiling Using Shotgun Metagenomic Sequencing Identified Unique Microorganisms in COVID-19 Patients With Altered Gut Microbiota

Gut Microbiota Improves Prognostic Prediction in Critically Ill COVID-19 Patients Alongside Immunological and Hematological Indicators

Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Fatality in COVID-19 Patients

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

Fecal multi-omics analysis reveals diverse molecular alterations of gut ecosystem in COVID-19 patients

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Gut Mycobiota Alterations in Patients with COVID-19 and H1N1 Infections and Their Associations with Clinical Features

The Faecal Metabolome in COVID-19 Patients is Altered and Associated with Clinical Features and Gut Microbes

Gut Microbiota Imbalance in Colorectal Cancer Patients, the Risk Factor of COVID-19 Mortality

Integrated Analysis of Gut Microbiome and Host Immune Responses in COVID-19

Dynamic Alterations in the Respiratory Tract Microbiota of Patients with COVID‐19 and its Association with Microbiota in the Gut

Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications

Assessment of Microbiota in the Gut and Upper Respiratory Tract Associated with SARS-CoV-2 Infection

Alterations in the human oral and gut microbiomes and lipidomics in COVID-19

Integrated gut virome and bacteriome dynamics in COVID-19 patients

Gut microbiota may underlie the predisposition of healthy individuals to COVID-19

Microbiome characteristics description of COVID-19 patients based on bulk RNA-seq and scRNA-Seq data

Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients

Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19

Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients